Months after world regulators first discovered impurities in the ingredient of a Chinese ingredient maker, tainted drugs continue to show up in the U.S. supply.
Genentech filed a lawsuit against former employees accused of stealing trade secrets, calling on a court to issue an injunction and award damages.
Hikma, which has established itself as a top sterile injectables manufacturer in the U.S., is now picking up a production plant in Vietnam.
While Mylan’s third-quarter results impressed analysts, the generics drugmaker is still dealing with some significant manufacturing issues.
Pennsylvania-based Recro Pharma has expanded its CDMO manufacturing, adding a 24,000-square-foot facility that includes high-potent processing.
The FDA issued a 22-page, 11-observation Form 483 to Akorn’s Parsippany, New Jersey, plant following a five-week inspection.
With generics expected soon for eye drug Restasis, Allergan has canceled a $200 million expansion at its Waco, Texas, manufacturing plant.
Mylan, Pfizer and the FDA notified U.S. healthcare providers of a potential problem with some EpiPens which can delay treatment.
Merck's RotaTeq won China approval in April and a launch is underway, but meanwhile, the company is reducing its shipments to low-income countries.
Here is some news of note for the week: Apotex is dangling a $10 million reward in its CEO’s murder.
